Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer

  • Authors:
    • Tadahiro Shoji
    • Eriko Takatori
    • Shinya Hatayama
    • Hideo Omi
    • Masahiro Kagabu
    • Tatsuya Honda
    • Seisuke Kumagai
    • Yuichi Morohara
    • Fumiharu Miura
    • Akira Yoshizaki
    • Toru Sugiyama
  • View Affiliations

  • Published online on: May 1, 2010     https://doi.org/10.3892/ol_00000091
  • Pages: 515-519
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to assess the antitumor response and safety of a tri-weekly neoadjuvant chemotherapy regimen consisting of cisplatin and irinotecan for the treatment of locally advanced cervical cancer with a bulky mass. Between June 2002 and March 2008, 20 patients with locally advanced squamous cell carcinoma of the uterine cervix at clinical stage Ib2-IIIb were studied. Two 21-day cycles consisting of intravenous administration of cisplatin at 70 mg/m2 (Day 1) and irinotecan at 70 mg/m2 (Days 1 and 8) were performed. Antitumor responses, adverse events and the surgery completion rate were investigated. The response rate of the 15 stage I-II patients was 86.7%, while that of the 5 stage III patients was 20%. Grade 3 or 4 neutropenia was noted in 12 patients, and 4 patients had grade 3 or 4 anemia. Queasiness and vomiting, as grade 3 or 4 non-hematotoxic events, occurred in 1 patient, but none of the patients had diarrhea. The surgery completion rate was 75%. The present data indicate that the tri-weekly cisplatin and irinotecan combination neoadjuvant chemotherapy involves only controllable toxicity and yields a high response rate, suggesting that this combination is a useful therapy regimen.
View Figures
View References

Related Articles

Journal Cover

May-June 2010
Volume 1 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shoji T, Takatori E, Hatayama S, Omi H, Kagabu M, Honda T, Kumagai S, Morohara Y, Miura F, Yoshizaki A, Yoshizaki A, et al: Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer. Oncol Lett 1: 515-519, 2010
APA
Shoji, T., Takatori, E., Hatayama, S., Omi, H., Kagabu, M., Honda, T. ... Sugiyama, T. (2010). Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer. Oncology Letters, 1, 515-519. https://doi.org/10.3892/ol_00000091
MLA
Shoji, T., Takatori, E., Hatayama, S., Omi, H., Kagabu, M., Honda, T., Kumagai, S., Morohara, Y., Miura, F., Yoshizaki, A., Sugiyama, T."Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer". Oncology Letters 1.3 (2010): 515-519.
Chicago
Shoji, T., Takatori, E., Hatayama, S., Omi, H., Kagabu, M., Honda, T., Kumagai, S., Morohara, Y., Miura, F., Yoshizaki, A., Sugiyama, T."Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer". Oncology Letters 1, no. 3 (2010): 515-519. https://doi.org/10.3892/ol_00000091